Pharmacogenomics of Medications for Pain and Major Depression: Promise and Peril

Size: px
Start display at page:

Download "Pharmacogenomics of Medications for Pain and Major Depression: Promise and Peril"

Transcription

1 Pharmacogenomics of Medications for Pain and Major Depression: Promise and Peril Geoffrey C. Wall, PharmD, FCCP, BCPS, CGP Professor of Clinical Sciences Drake University College of Pharmacy and Health Sciences Internal Medicine Clinical Pharmacist Iowa Methodist Medical Center, Des Moines, IA Disclosure Geoffrey Wall reports no actual or potential conflicts of interest associated with this presentation 1

2 Learning Objective Upon successful completion of this activity, pharmacists should be able to: Review the literature for evidence for or against pharmacogenomic testing for pain and psychiatric medications. Identify the specific tests that may guide medication selection and dose adjustment for pain and psychiatric medication. Apply the findings of pharmacogenomic testing to a patient case involving pain and psychiatric medications. Summing up the Potential of Pharmacogenomics 2

3 Pharmacogenomics Information in the Published Literature Zineh I et al. Ann Pharmacother. 2006; 40: Pharmacogenomics in Pain/Mental Health: Where are we? The Promise The testing is designed to improve the effectiveness of prescribing. These tests also will allow us to identify patients who might experience adverse effects from antidepressant or antipsychotic medications and may help to improve adherence Julia Bartlow, RPh. Genoa Health Cost per sample $ The Peril We don t really yet know how to use pharmacogenomic data to improve medication options for people with psychiatric illness. Right now we have identified a lot of biomarkers, which means that one day we should be able to improve medication options with these tests. But little of what we have so far is definitive Shaili Jain, MD, psychiatrist at VA Palo Alto Accessed 7/29/15http:// 3

4 Clinical Relevance Can we predict who will derive an optimal response? Can we predict who will have a toxicity? Host (patient) genotype determines optimal drug therapy approach Disease (pathogen) genotype determines optimal drug therapy approach State of the Evidence What we have PK/PD studies in small numbers of patients Retrospective studies looking at genomic characteristics of patients AFTER a study has been done Prospective studies with adjunctive genomic testing What we need RCTs that compare PGx guided dosing with usual care 4

5 PGX AND PAIN Pain Management Genetic Analysis ABCB1=ATP-binding cassette, subfamily B, member 1 OPRM1=mu-opioid receptor gene COMT=catechol-O-methyltransferase UGT=uridine 5 -diphosphate-glucuronosyltransferase Jannetto P, et al. Expert Opin Drug Metab Toxicol. 2011; 7:

6 CYP2D6 Polymorphisms CYP2D6 is responsible for the metabolism of a number of different drugs Antidepressants, antipsychotics, analgesics, cardiovascular drugs Over 100 polymorphisms in CYP2D6 have been identified Based on these polymorphisms, patients are phenotypically classified as: Ultrarapid metabolizers (UMs) Extensive metabolizers (EMs) Intermediate metabolizers (IMs) Poor metabolizers (PMs) Opioid Metabolism: CYP450 variations Phase I metabolism in liver CYP2D6, CYP3A4, CYP2C19, and others Spectrum of enzymatic activity Poor, intermediate, extensive, ultra rapid Tramadol to active metabolite via -2D6 Codeine conversion to morphine via -2D6 Oxycodone to active metabolite via -2D6 Jannetto P, et al. Expert Opin Drug Metab Toxicol. 2011; 7: Ma J, et al. Journal of Pharmacy Practice. 2012; 25:

7 Clinical Example: CYP2D6 and Codeine Codeine requires activation by CYP2D6 in order to exert its analgesic effect Due to genetic polymorphisms, 2-10% of the population cannot metabolize codeine and are resistant to the analgesic effects Individual variability exists in the adequacy of pain relief when uniform doses of codeine are given CPIC 2014 Guidelines on PGx Dosing and Codeine Crews KR, et al Clin Pharm and Therapeutics 2014;95:

8 CYP2D6 Phenotypes Roden DM et al. Ann Intern Med 2006; 145: Ethnic Variation in 2D6 Metabolism 8

9 CYP2D6 Phenotype Correlation Gaston C and Kolesar J. Clin Adv Hematol Oncol. 2008;6: Study: Tramadol and PGx Prospective OL trial in postoperative pain in adults n = 271 2D6 profiles in all patients then given PCA with tramadol (IV where study was conducted) Outcome: 24 pain usage/scores and rescue medication Results: PM vs EM Non-responders: 47% vs. 22% (p = 0.005) Needing rescue meds: 43% vs. 22% (p < 0.001) Stamer UM, et al. Pain. 2003; 105:

10 PGx Targets Summary Jannetto P et al. Expert Opin Drug Metab Toxicol. 2011; 7: CYP2D6: Amitriptyline and Nortriptyline Amitriptyline is metabolized by both CYP2D6 and CYP2C19. Nortriptyline is metabolized by CYP2D6. Altered metabolism for CYP2D6 and CYP2C19 may warrant a change in dose or use of an alternate agent. CYP2D6 ultra-rapid metabolizers have a higher probability of failing amitriptyline or nortriptyline therapy due to subtherapeutic plasma concentrations. CYP2D6 poor metabolizers may have a higher risk of adverse events due to elevated plasma concentrations Kapur BM, et al. Clin Biochem. 2014;47:

11 PGx and Other Pain Medications NSAIDs Many metabolized by 2D6 Polymorphisms may lead in increased ADRs COX-1 and COX-2 encoded by different genes different genotypes may lead to better response to NSAIDs Kapur BM, et al. Clin Biochem. 2014;47: PGX AND MAJOR DEPRESSION 11

12 CYP2D6 Polymorphisms and Psychiatric Drug Response Increased rate of adverse effects in poor metabolizers due to increased plasma concentrations of drug: Fluoxetine death in child attributed to CYP2D6 poor metabolizer genotype Side effects of antipsychotic drugs occur more frequently in CYP2D6 poor metabolizers CYP2D6 poor metabolizers with severe mental illness had more adverse drug reactions, increased cost of care, and longer hospital stays JC Stingl et al, Mol Psych 2012,

13 Systematic Review of CYP/PGx and Antidepressants Porcelli S, et al. J Psychiatry Neurosci. 2011;36: P-gp polymorphisms and response to antidepressants Antidepressants need to pass the BBB to get to the brain They do so via carrier molecules like P-gp Study: 362 patients treated with P-gp substrates (amitriptyline, citalopram, paroxetine, venlafaxine) or nonsubstrate (mirtazapine) 9.5% non-remitters carried C allele vs 45% of remitters C-carriers treated with P-gp substrate significant increased risk of remission Uhr, M. et al. Neuron 2008; 57:

14 Pharmacodynamics and PGx Tryptophan hydroxylase (TPH) Catalyzes 5-HT Biosynthesis TPH1*a allele associated with decreased 5-HT Catechol-O-methyl transferase (COMT) rs4680 polymorphism associated with worse outcomes and increased suicidality 5-HTT Serotonin Transporter 5-HTTLPR polymorphism associated with a wide variety of psychiatric disorders The most studied PD variable in PGx studies Porcelli S, et al. J Psychiatry Neurosci. 2011;36: SSRIs and 5-HTTLPR Schosser A, et al.int Clin Psychopharmacol ;24:

15 The Evidence for PGx in MDD 233 adult patients with MDD via DSM-IV OL design Patients consecutively assigned to usual care or PGx guided therapy Testing done on both cohorts but prescribers only received the results in one cohort Multiple instruments to detect response (e.g HAM-D) Standard if complex statistics Hall-Flavin DK, et al. Pharmacogenet Genomics. 2013;23: Example of PGx Report 15

16 Aetna considers genotyping for other cytochrome P450 polymorphisms including antipsychotic medications, and selective serotonin reuptake inhibitors experimental and investigational because the clinical value of this type of genetic testing has not been established. Aetna considers genotyping for HLA-B* 1502 medically necessary for persons of Asian ancestry before commencing treatment with carbamazepine (Tegretol). - Last update 8/

17 Conclusions Many studies showing association of PGx with pain/depression and treatments Virtually no data showing pharmacotherapy via this method is superior to standard dosing PGx is just one factor Not yet ready for prime time Medicare B will cover Pgx testing in some select cases Kapur BM, et al. Clin Biochem. 2014;47: Here s my sequence Maybe one day soon 17

18 CPE Instructions Logon to Click on My Profile. Locate the activity title you wish to complete within your Profile and click on Exam. Complete the Exam and Evaluation as prompted; click SUBMIT to send your information to CPE Monitor. There is no code associated with this activity. All participants were to have pre-registered on the CEI website. Once your credit has been claimed, the activity will move to your Completed Activities. 18

Pharmacogenetics in: Primary Care. Bradley T. Wajda D.O.

Pharmacogenetics in: Primary Care. Bradley T. Wajda D.O. Pharmacogenetics in: Primary Care Bradley T. Wajda D.O. Pharmacogenomics Defined Pharmacogenomics uses information about a person s genetic makeup, or genome, to choose the drugs and drug doses that are

More information

Mental Health DNA Insight WHITE PAPER

Mental Health DNA Insight WHITE PAPER Mental Health DNA Insight WHITE PAPER JULY 2016 Mental Health DNA Insight / White Paper Mental Health DNA Insight Pathway Genomics Mental Health DNA Insight test is aimed to help psychiatrists, neurologists,

More information

Psychiatric Pharmacogenomics: Introduction and Applications

Psychiatric Pharmacogenomics: Introduction and Applications Psychiatric Pharmacogenomics: Introduction and Applications Moises Gaviria, MD Distinguished Professor of Psychiatry University of Illinois at Chicago Medical Director The Institute of Neurobehavioral

More information

Two decades of clinical pharmacogenetic testing - Where do we stand?

Two decades of clinical pharmacogenetic testing - Where do we stand? Two decades of clinical pharmacogenetic testing - Where do we stand? Marja-Liisa Dahl, MD PhD, Professor Dept of Clinical Pharmacology Karolinska University Hospital/Karolinska Institutet Stockholm, Sweden

More information

Pharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA

Pharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA Pharmacogenetics of Codeine Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA 1 Codeine Overview Naturally occurring opium alkaloid Demethylated to morphine for analgesic effect

More information

3. Describe how variants in the CYP2C19 gene impact Plavix metabolism. 4. Compare molecular genetic technologies for pharmacogenomics testing

3. Describe how variants in the CYP2C19 gene impact Plavix metabolism. 4. Compare molecular genetic technologies for pharmacogenomics testing UP! UNDERSTANDING PHARMACOGENOMICS (PGX) Robert Pyatt Ph.D., Director Sanford Medical Genetics and Genomics Laboratories and Associate Professor, Dept of Internal Medicine, University of South Dakota April

More information

Pharmacogenomics of Antidepressant Medications

Pharmacogenomics of Antidepressant Medications Research Reviews: Pharmacy and Pharmaceutical Sciences e-issn: 2320-1215 www.rroij.com Pharmacogenomics of Antidepressant Medications Amanpreet Kooner and Inder Sehgal* California Health Sciences, University

More information

Membership Overview: Total Members: 322 Student Members: 160 Resident Members: 8 Fellow Members: 4

Membership Overview: Total Members: 322 Student Members: 160 Resident Members: 8 Fellow Members: 4 A Closer Look at the Central Nervous System PRN Overview of the PRN The Central Nervous System Practice and Research Network (CNS PRN) provides a forum to encourage networking among pharmacists specializing

More information

WHAT S NEW. Vilazodone (Viibryd ) Vilazodone - Dosing ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics?

WHAT S NEW. Vilazodone (Viibryd ) Vilazodone - Dosing ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics? ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics? Rex S. Lott, Pharm.D., BCPP Professor, ISU College of Pharmacy Mental Health Clinical Pharmacist, Boise VAMC

More information

Opioid Use: Current Challenges & Clinical Advancements

Opioid Use: Current Challenges & Clinical Advancements Opioid Use: Current Challenges & Clinical Advancements Whitney Bergquist, PharmD, MBA, BCPS Acute Care NPPA Conference February 8, 2017 2017 MFMER slide-1 No Disclosures 2017 MFMER slide-2 Objectives Summarize

More information

Pharmacogenetic Testing in Psychiatry Jose de Leon, MD ( )

Pharmacogenetic Testing in Psychiatry Jose de Leon, MD ( ) Pharmacogenetic Testing in Psychiatry Jose de Leon, MD (12-01-15) Conflicts of Interest (See more details on conflict of interest in the first presentation Training Psychiatrists to Think like Pharmacologists

More information

Genetics and Genomics: Influence on Individualization of Medication Regimes

Genetics and Genomics: Influence on Individualization of Medication Regimes Genetics and Genomics: Influence on Individualization of Medication Regimes Joseph S Bertino Jr., Pharm.D., FCCP Schenectady, NY USA Goals and Objectives To discuss pharmacogenetics and pharmacogenomics

More information

I have NO actual or potential conflicts of interest in relation to this educational presentation.

I have NO actual or potential conflicts of interest in relation to this educational presentation. Genotyping The Patient Requiring Mental Health Medications: When Does It Make Sense? Charles F. Caley, PharmD, BCPP Clinical Professor UConn School of Pharmacy Storrs, CT I have NO actual or potential

More information

Mujeeb U. Shad, M.D., M.S.C.S. Associate Professor of Psychiatry Oregon Health & Science University, Portland Oregon Supervising Psychiatrist Oregon

Mujeeb U. Shad, M.D., M.S.C.S. Associate Professor of Psychiatry Oregon Health & Science University, Portland Oregon Supervising Psychiatrist Oregon Mujeeb U. Shad, M.D., M.S.C.S. Associate Professor of Psychiatry Oregon Health & Science University, Portland Oregon Supervising Psychiatrist Oregon State Hospital, Salem Oregon Assurex Health Inc. has

More information

Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence

Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole

More information

They deserve personalized treatment

They deserve personalized treatment Your patients are unique They deserve personalized treatment New laboratory service offered by STA 2 R is a panel of genetic tests that gives prescribers answers to the clinical questions below. The test

More information

Pharmacogenomics In Psychiatry. Wolfgang Sadee OSU Program in Pharmacogenomics The Ohio State University. XGEN Group NIH PGRN

Pharmacogenomics In Psychiatry. Wolfgang Sadee OSU Program in Pharmacogenomics The Ohio State University. XGEN Group NIH PGRN Pharmacogenomics In Psychiatry Wolfgang Sadee OSU Program in Pharmacogenomics The Ohio State University XGEN Group NIH PGRN Why do we need biomarkers in drug therapy? Limited efficacy Adverse drug effects

More information

Objectives. Clinical Problem. What if there were a way. Pharmacogenomics in Current Practice MEDICINE 12/1/2017

Objectives. Clinical Problem. What if there were a way. Pharmacogenomics in Current Practice MEDICINE 12/1/2017 Objectives Pharmacogenomics in Current Practice Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Review the concept of pharmacogenetics and pharmacogenomics

More information

Pharmacogenomics in Current Practice. Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy.

Pharmacogenomics in Current Practice. Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy. Pharmacogenomics in Current Practice Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Objectives Review the concept of pharmacogenetics and pharmacogenomics

More information

Pharmacogenetics Implementation at Cincinnati Children s Hospital Medical Center (CCHMC)

Pharmacogenetics Implementation at Cincinnati Children s Hospital Medical Center (CCHMC) Pharmacogenetics Implementation at Cincinnati Children s Hospital Medical Center (CCHMC) Laura Ramsey, PhD Co-Director, Genetic Pharmacology Service Assistant Professor Divisions of Research in Patient

More information

Review of Pharmacogenetic Testing Today

Review of Pharmacogenetic Testing Today Review of Pharmacogenetic Testing Today Gwen McMillin, PhD ARUP Laboratories University of Utah Salt Lake City, Utah A customer says to the pharmacist: "Why does my medication have 40 side effects?" The

More information

Personalized Prescribing: Using Genetic Testing to Guide Drug and Dose Selection. Lindsay S. Elliott, Pharm.D., CGP

Personalized Prescribing: Using Genetic Testing to Guide Drug and Dose Selection. Lindsay S. Elliott, Pharm.D., CGP Personalized Prescribing: Using Genetic Testing to Guide Drug and Dose Selection Lindsay S. Elliott, Pharm.D., CGP Disclosure I, Lindsay Elliott, am a pharmacy consultant for Genelex Corporation in conducting

More information

CORE DME PANEL Highlands Parkway, Suite 100 Smyrna, GA 30082

CORE DME PANEL Highlands Parkway, Suite 100 Smyrna, GA 30082 CORE DME PANEL Castle's CORE DME panel predicts the activity levels of key - drug metabolizing enzymes in the cytochrome P450 superfamily: CYP2D6, CYP2C9, CYP2C19, CYP2B6, CYP3A4, and - CYP3A5. Apart from

More information

Psychotropic & Unnecessary Medication Reduction: Living Longer Better : Utilizing The Clinical Tool of Metabolic Validation Testing

Psychotropic & Unnecessary Medication Reduction: Living Longer Better : Utilizing The Clinical Tool of Metabolic Validation Testing Psychotropic & Unnecessary Medication Reduction: Living Longer Better : Utilizing The Clinical Tool of Metabolic Validation Testing CMS NEWEST GUIDELINES CMS will push nursing homes to reduce their use

More information

Pharmacogenomics and Cultural Issues! Y. W. Francis Lam, Pharm.D., FCCP!

Pharmacogenomics and Cultural Issues! Y. W. Francis Lam, Pharm.D., FCCP! Pharmacogenomics and Cultural Issues in Psychopharmacology Y. W. Francis Lam, Pharm.D., FCCP 1 Pharmacogenomics and Cultural Issues in Psychopharmacology Y. W. Francis Lam, Pharm.D., FCCP Professor of

More information

Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?

Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Prof. Dr. Christoph Hiemke Psychiatrische Klinik und Poliklinik Universität Mainz Psychopharmacotherapy Psychiatric Patient

More information

6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES

6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES 6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES Ron H.N. van Schaik Dept. Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands 6.1 Introduction In today s medicine, drug therapy represents

More information

Are health care systems ready to deliver pharmacogenetics as standard of care? Predicting the needs and setting the strategies

Are health care systems ready to deliver pharmacogenetics as standard of care? Predicting the needs and setting the strategies Are health care systems ready to deliver pharmacogenetics as standard of care? Predicting the needs and setting the strategies David Gurwitz Sackler Faculty of Medicine, Tel-Aviv University, Israel OECD,

More information

Pharmacogenomics: Genetic variations in drug metabolism and utilization. Disclosure

Pharmacogenomics: Genetic variations in drug metabolism and utilization. Disclosure Pharmacogenomics: Genetic variations in drug metabolism and utilization Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC, FNAP President, Fitzgerald Health Education Associates, North Andover,

More information

Application of Pharmacogenetics Supplementary Worksheet

Application of Pharmacogenetics Supplementary Worksheet Application of Pharmacogenetics Supplementary Worksheet Section 1 Health Care Problem Section 2 Drug Metabolism Section 3 Phase I & II metabolism Section 4 Inhibitors and Inducers Section 5 DNA & Drug

More information

Pharmacogenomics and Clinical Practice: Ready for Prime Time? Disclosures. Elder-Friendly Futures Conference 2013 A UW Gerontology Conference

Pharmacogenomics and Clinical Practice: Ready for Prime Time? Disclosures. Elder-Friendly Futures Conference 2013 A UW Gerontology Conference Pharmacogenomics and Clinical Practice: Ready for Prime Time? Manju T. Beier, Pharm D, CGP, FASCP Chief Scientific Officer Natural Molecular Testing Corp. Adjunct Clinical Associate Professor of Pharmacy

More information

CYP2D6: mirtazapine 2001/2002/2003

CYP2D6: mirtazapine 2001/2002/2003 CYP2D6: mirtazapine 2001/2002/200 Cl or = oral clearance,=c ss = steady state concentration, EM = extensive metaboliser, IM = intermediate metaboliser, MR = metabolic ratio, NS = non-significant, PM =

More information

Biomarkers for Psychiatric Drug Toxicity. Oct 24, 2008 Thomas R. Insel, M.D. Director, NIMH

Biomarkers for Psychiatric Drug Toxicity. Oct 24, 2008 Thomas R. Insel, M.D. Director, NIMH Biomarkers for Psychiatric Drug Toxicity Oct 24, 2008 Thomas R. Insel, M.D. Director, NIMH Burden of Disease (DALYs) U.S., Canada, and Western Europe 15-44 years old Mental Illness* Injuries, including

More information

Implementing Pharmacogenetic Testing Into Clinical Laboratories. Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories

Implementing Pharmacogenetic Testing Into Clinical Laboratories. Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories Implementing Pharmacogenetic Testing Into Clinical Laboratories Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories Key learning objectives Recognize decisions in implementing pharmacogenetic

More information

Psychiatric genomics 2018: what the clinician needs to know

Psychiatric genomics 2018: what the clinician needs to know Li_benefit VPA_benefit cbz_benefit Lam_benefit Combo_ms_benefit Olz_benefit Cloz_benefit Ris_benefit Quet_benefit Ari_benefit Zip_benefit Asen_benefit Luras_benefit Pali_benefit Fluphen_benefit Haldol_benefit

More information

Pharmacogenomics and Customized Therapies in Psychiatry

Pharmacogenomics and Customized Therapies in Psychiatry Pharmacogenomics and Customized Therapies in Psychiatry Toshiyuki Someya,, MD, PhD Department of Psychiatry Niigata University Graduate School of Medical and Dental Sciences The efficacy and side effects

More information

Clinical Pharmacogenomics in Depression Treatment

Clinical Pharmacogenomics in Depression Treatment Clinical Pharmacogenomics in Depression Treatment GORDON ANG, PHARMD PGY- 2 PSYCHIATRIC PHARMACY RESIDENT CENTRAL TEXAS VETERANS HEALTH CARE SYSTEM 1 Abbreviations CGI-S: Clinical Global Impression Severity

More information

Pharmacogenomics and Clinical Practice: Ready for Prime Time?

Pharmacogenomics and Clinical Practice: Ready for Prime Time? Pharmacogenomics and Clinical Practice: Ready for Prime Time? Manju T. Beier, Pharm D, CGP, FASCP Chief Scientific Officer Natural Molecular Testing Corp. Adjunct Clinical Associate Professor of Pharmacy

More information

Precision Medicine in Mental Health Care

Precision Medicine in Mental Health Care Precision Medicine in Mental Health Care Study PI: David Oslin, MD 11/21/17 Background: Public Health Significance Depression is one of the world s great public health problems At least 1 in 7 Veterans

More information

General Discussion 4

General Discussion 4 General Discussion 4 General Discussion 115 Introduction Psychiatry is considered to be one of the first medical disciplines that will implement pharmacogenetic testing in daily clinical practice. The

More information

Big Data Course Week 7 Test2Learn TM 5/7/16

Big Data Course Week 7 Test2Learn TM 5/7/16 The site is http://api.test2learn.com Usernames are first letter of first-name + first 3 letters of last name (i.e. John Smith would be jsmi ) Passwords are the same as the usernames. Everyone will need

More information

Pharmacogenomics and Pharmacokinetics ^

Pharmacogenomics and Pharmacokinetics ^ Pharmacogenomics and Pharmacokinetics ^ avid F. Kisor, B.S., Pharm.. Profeor of Pharmacokinetics epartment of Pharmaceutical and Biomedical Sciences Raabe College of Pharmacy Ohio Northern University Learning

More information

American Psychiatric Nurses Association

American Psychiatric Nurses Association Francis J. McMahon International Society of Psychiatric Genetics Johns Hopkins University School of Medicine Dept. of Psychiatry Human Genetics Branch, National Institute of Mental Health* * views expressed

More information

Pharmacogenetics: LabQuality Days Helsinki, February 8, Do you have your DNA passport? Prof Dr Ron van Schaik

Pharmacogenetics: LabQuality Days Helsinki, February 8, Do you have your DNA passport? Prof Dr Ron van Schaik LabQuality Days Helsinki, February 8, 2018 Pharmacogenetics: Do you have your DNA passport? Prof Dr Ron van Schaik International Expert Center Pharmacogenetics Dept Clinical Chemistry - Erasmus MC Rotterdam,

More information

Genetic Testing for Diagnosis and Management of Mental Health Conditions

Genetic Testing for Diagnosis and Management of Mental Health Conditions Genetic Testing for Diagnosis and Management of Mental Health Conditions Policy Number: Original Effective Date: MM.02.026 07/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration

More information

SAMPLE REPORT MENTAL HEALTH DNA INSIGHT LABORATORY INFO. Protected Health Information. SSRIs. TCAs. Other Antidepressants

SAMPLE REPORT MENTAL HEALTH DNA INSIGHT LABORATORY INFO. Protected Health Information. SSRIs. TCAs. Other Antidepressants Test Results Reviewed & Approved by: Laboratory Director, Nilesh Dharajiya,.D. ENTAL HEALTH DNA INSIGHT PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROFESSIONAL Glenn Braunstein.D.

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Genetic Testing for Mental Health Conditions File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_mental_health_conditions 1/2014 6/2017 6/2018

More information

Deliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing

Deliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing GA N 668353 H2020 Research and Innovation Deliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing WP N and Title: WP2 - Towards shared European Guidelines for PGx Lead beneficiary:

More information

Drug-Drug Interactions in Psychiatry

Drug-Drug Interactions in Psychiatry Drug-Drug Interactions in Psychiatry John J. Miller, M.D. Medical Director, Brain Health Exeter, NH Acknowledgement Some of the slides used in this presentation were created by Jessica R. Oesterheld, MD.

More information

Over the last 50 years, the scientific and medical community has

Over the last 50 years, the scientific and medical community has Precision medicine and pharmacogenomics in community and primary care settings Over the last 50 years, the scientific and medical community has seen the field of pharmacogenomics and precision medicine

More information

Genetic Testing for Mental Health Conditions

Genetic Testing for Mental Health Conditions Genetic Testing for Mental Health Conditions Policy Number: Original Effective Date: MM.02.026 07/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/01/2015 Section: Medicine

More information

Article. Reference. Applications of CYP450 Testing in the Clinical Setting. SAMER, Caroline Flora, et al.

Article. Reference. Applications of CYP450 Testing in the Clinical Setting. SAMER, Caroline Flora, et al. Article Applications of CYP450 Testing in the Clinical Setting SAMER, Caroline Flora, et al. Abstract Interindividual variability in drug response is a major clinical problem. Polymedication and genetic

More information

FEP Medical Policy Manual

FEP Medical Policy Manual FEP Medical Policy Manual Effective Date: October 15, 2018 Related Policies: 2.04.38 Cytochrome P450 Genotype-Guided Treatment Strategy Genotype-Guided Tamoxifen Treatment Description Tamoxifen is prescribed

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist

More information

Professor John F. Peppin, DO, FACP Marian University, College of Osteopathic Medicine, Adjunct Faculty

Professor John F. Peppin, DO, FACP Marian University, College of Osteopathic Medicine, Adjunct Faculty Professor John F. Peppin, DO, FACP Marian University, College of Osteopathic Medicine, Adjunct Faculty The most important goal of medicine, and health care in general, is to relieve patient suffering.

More information

Objectives Making CYP450, Drug Interactions, & Pharmacogenetics Easy

Objectives Making CYP450, Drug Interactions, & Pharmacogenetics Easy Objectives Making, Drug Interactions, & Pharmacogenetics Easy Anthony J. Busti, MD, PharmD, FNLA, FAHA Describe the differences between phase I and phase II metabolic pathways. Identify the most common

More information

Self Assessment Question 1

Self Assessment Question 1 Drug Interactions Bruce G. Pollock, M.D., Ph.D. Professor of Psychiatry, Pharmacology and Nursing Chief, Academic Division of Geriatrics and Neuropsychiatry University of Pittsburgh Medical Center 1 Self

More information

Risperidone Case 1: Drug-Drug Interactions

Risperidone Case 1: Drug-Drug Interactions Risperidone Case 1: Drug-Drug Interactions 1-14-16 de Leon & Bork (a resident) J Clin Psychiatry 1997;58:450-1 http://www.ncbi.nlm.nih.gov/pubmed/9375597 Jose de Leon, MD Educational Objectives At the

More information

Pharmacogenomics Gene/Drug-Pair Decision Flow Charts 2017

Pharmacogenomics Gene/Drug-Pair Decision Flow Charts 2017 Pharmacogenomics Gene/Drug-Pair Decision Flow Charts 2017 Atomoxetine Prescription CYP2D6 Genotype (AS = 0) (AS = 0.5 1.0) (As = 2.0) Ultrarapid (AS >2.0) Standard dose. Dose increase probably not necessary;

More information

Pharmacogenetics: DNA analysis. to explain / predict. response to drug therapy. Maurizio Ferrari & Ron van Schaik

Pharmacogenetics: DNA analysis. to explain / predict. response to drug therapy. Maurizio Ferrari & Ron van Schaik Maurizio Ferrari & Ron van Schaik Workshop IFCC Kuala Lumpur November 19, 2012 Predictive, Preventive and Personalized Medicine Part II: Pharmacogenetics l r.vanschaik@erasmusmc.nl Pharmacogenetics: DNA

More information

The Role of Pharmacogenomics to Guide Treatment in Mood and Anxiety Disorders

The Role of Pharmacogenomics to Guide Treatment in Mood and Anxiety Disorders Curr Behav Neurosci Rep (2015) 2:154 164 DOI 10.1007/s40473-015-0048-z MOOD AND ANXIETY DISORDERS (D IOSIFESCU, SECTION EDITOR) The Role of Pharmacogenomics to Guide Treatment in Mood and Anxiety Disorders

More information

Pharmacogenetics and clinical opioid efficacy. Pål l Klepstad Professor of Intensive Care Medicine St.Olavs University Hospital Trondheim,, Norway

Pharmacogenetics and clinical opioid efficacy. Pål l Klepstad Professor of Intensive Care Medicine St.Olavs University Hospital Trondheim,, Norway Pharmacogenetics and clinical opioid efficacy Pål l Klepstad Professor of Intensive Care Medicine St.Olavs University Hospital Trondheim,, Norway Variation in opioid dose Variation in effects from different

More information

Psychiatric genomics 2016: what the clinician needs to know

Psychiatric genomics 2016: what the clinician needs to know Psychiatric genomics 2016: what the clinician needs to know Roy Perlis, MD MSc Center for Experimental Drugs and Diagnostics MGH Department of Psychiatry MGH Center for Human Genetic Research rperlis@partners.org

More information

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response (2004) 9, 442 473 & 2004 Nature Publishing Group All rights reserved 1359-4184/04 $25.00 www.nature.com/mp FEATURE REVIEW Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic

More information

New Advances in Psychiatric Genetics Joseph Shen, M.D., Ph.D. Aisha Furqan, LCGC Clinical Genetics UCSF-Fresno Community Regional Medical Center

New Advances in Psychiatric Genetics Joseph Shen, M.D., Ph.D. Aisha Furqan, LCGC Clinical Genetics UCSF-Fresno Community Regional Medical Center New Advances in Psychiatric Genetics Joseph Shen, M.D., Ph.D. Aisha Furqan, LCGC Clinical Genetics UCSF-Fresno Community Regional Medical Center Background Genetic testing Treatment options: Pharmacogenetics

More information

2/28/2010. Pharmacogenomics and the Asian Population. Limited efficacy/response to drugs already on the market

2/28/2010. Pharmacogenomics and the Asian Population. Limited efficacy/response to drugs already on the market Pharmacogenomics and the Asian Population Majority are medication related Alan H.B. Wu, Ph.D. Professor, Laboratory Medicine, UCSF Section Chief, Clinical Chemistry, February 27, 20 Limited efficacy/response

More information

BEHAVIORAL HEALTH GENOTYPING REPORT

BEHAVIORAL HEALTH GENOTYPING REPORT Health, Sally; DOB: 09/05/1988 PAGE 1 OF 5 BEHAVIORAL HEALTH GENOTYPING REPORT Patient Name: Health, Sally Date Sample Collected: 06/27/14 DOB: 09/05/1988 Date Sample Received: 07/04/14 Lab ID Number:

More information

Personalized Genomic Medicine: What is it? Why should I care? How can I use it?

Personalized Genomic Medicine: What is it? Why should I care? How can I use it? Friday, October 17, 2014 Olli Lifelong Learning Health Education Series Lunch and Learn UNC-Asheville Campus Lynn G. Dressler, Dr.P.H. Director, Personalized Medicine Mission Health Fullerton Genetics

More information

Taking the Pain Out of Pain Management Testing

Taking the Pain Out of Pain Management Testing Taking the Pain ut of Pain Management Testing Welcome Taking the Pain ut of Pain Management Testing ctober 5, 2010 Your Host: Karen Riba Handout available by clicking on handout icon, in upper right hand

More information

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Cytochrome p450 Genotyping Page 1 of 24 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: See Also: Cytochrome p450 Genotyping Genetic Testing for Helicobacter

More information

Cytochrome p450 Genotyping. Description. Section: Medicine Effective Date: July 15, 2015

Cytochrome p450 Genotyping. Description. Section: Medicine Effective Date: July 15, 2015 2.04.38 Subject: Cytochrome p450 Genotyping Page: 1 of 30 Last Review Status/Date: June 2015 Cytochrome p450 Genotyping Description The cytochrome p450 (CYP450) family is involved in the metabolism of

More information

Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing

Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing Brian Thomas Hocum, Pharm.D., CGP, Genelex Corporation, Seattle, WA (bhocum@genelex.com). John Raymond

More information

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College

More information

Uridine Diphosphate Glucuronosyltransferase 1A1 (UGT1A1) Pharmacogenetic Competency

Uridine Diphosphate Glucuronosyltransferase 1A1 (UGT1A1) Pharmacogenetic Competency Uridine Diphosphate Glucuronosyltransferase 1A1 (UGT1A1) Pharmacogenetic Competency Updated on 7/2015 General Tips for Viewing Material Upon completion of the educational material, close out the presentation

More information

Supplement to: Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC ) for CYP2D6

Supplement to: Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC ) for CYP2D6 Supplement to: Pharmacogenetics Implementation Consortium Guideline (CPIC ) for CYP2D6 and CYP2C19 Genotypes and Tricyclic Antidepressants: 2016 Update J. Kevin Hicks 1, Katrin Sangkuhl 2, Jesse J. Swen

More information

Right drug. Right dose. Right now. Delivering on the promise and value of personalized prescribing

Right drug. Right dose. Right now. Delivering on the promise and value of personalized prescribing Right drug. Right dose. Right now. Delivering on the promise and value of personalized prescribing 2 Table of Contents Part One: Pharmacogenetics 101...Slides 4-16 Time Requirement: 20 minutes Part Two:

More information

Memorandum. Claims Payment and Clinical Policy Clarification. Question/Issue:

Memorandum. Claims Payment and Clinical Policy Clarification. Question/Issue: Memorandum To: PerformCare Provider Network From: Scott Daubert PhD, VP Operations Date: August 1, 2015 Subject: PC-17 Pharmacogenomics tests for psychiatric medications Claims Payment and Clinical Policy

More information

Cardiovascular pharmacogenomics: ready for prime time?

Cardiovascular pharmacogenomics: ready for prime time? Cardiovascular pharmacogenomics: ready for prime time? Simon de Denus, pharmacist, MSc (Pharm), PhD Université de Montréal Beaulieu-Saucier Chair in Pharmacogenomics Assistant professor, Faculty of Pharmacy,

More information

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY Original Issue Date (Created): October 1, 2014 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT

More information

Cytochrome p450 Genotyping

Cytochrome p450 Genotyping Cytochrome p450 Genotyping Policy Number: Original Effective Date: MM.02.004 04/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/18/2015 Section: Medicine Place(s) of

More information

SAMPLE REPORT MENTAL HEALTH DNA INSIGHT

SAMPLE REPORT MENTAL HEALTH DNA INSIGHT PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROFESSIONAL Glenn Braunstein.D. 6777 Nancy Ridge Drive San Diego, CA 92121 US LABORATORY INFO ACCESSION NUBER ACTIVATION CODE SPECIEN

More information

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College

More information

Rational Polypharmacy

Rational Polypharmacy Rational Polypharmacy Thomas B. Gregory, PharmD, BCPS, CPE, FASPE Disclosures Clinical advisory board: Daiichi Sankyo 1 Introduction Cox Health Ambulatory Pain Clinic Pharmacy Specialist Learning Objectives

More information

Core Data Set CYP2D6 Metabolism

Core Data Set CYP2D6 Metabolism Core Data Set CYP2D6 Metabolism Oxidised metabolites seen in pre-clinical species Inhibitor Target CYP Isoform CLint (µl/min/mg protein) % Inhibition Control 12.5 - Furafylline 1A2 12.9 0 Sulfaphenoxazole

More information

An Introduction to Principles and Practice July 8, Presented by

An Introduction to Principles and Practice July 8, Presented by An Introduction to Principles and Practice July 8, 2011 Presented by Biomarkers in Psychiatry Jay Lombard, DO Chief Scientific Officer and Medical Director Genomind 2 Our mission is to advance the care

More information

CYP2D6 Genotype to Phenotype Standardization Project

CYP2D6 Genotype to Phenotype Standardization Project CYP2D6 Genotype to Phenotype Standardization Project Project Objectives Determine a strategy for defining CYP2D6 phenotype based on genotype using a modified Delphi method. Standardize phenotype definitions

More information

Imipramine therapy (CYP2D6)

Imipramine therapy (CYP2D6) Imipramine therapy (CYP2D6) Intake Start therapy 1st conc 08:00 2nd conc 3e spiegel 4e spiegel 1 week 1 week 1 week 1 week 1 week 22:00 ~ 50% patients need dose adjustment Imipramine therapy (CYP2D6) Intake

More information

Objectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS

Objectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private

More information

Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study

Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study For reprint orders, please contact: reprints@futuremedicine.com Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study Theresa R Tonozzi

More information

MEDICATION ALGORITHM FOR ANXIETY DISORDERS

MEDICATION ALGORITHM FOR ANXIETY DISORDERS Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON

More information

Ron van Schaik. Pharmacogenetics. London, Oct 8-9, Clinical implementation: a 7 year experience

Ron van Schaik. Pharmacogenetics. London, Oct 8-9, Clinical implementation: a 7 year experience Ron van Schaik Associate Professor Pharmacogenetics Eur Clin Chem / Advisor EMA - PGWG London, Oct 8-9, 2012 Pharmacogenetics Clinical implementation: a 7 year experience Pharmacogenetics Core Laboratory*

More information

MMG004 GUIDELINES FOR THE USE OF HIGH DOSE VENLAFAXINE AND THE COMBINATION OF VENLAFAXINE AND MIRTAZAPINE IN THE TREATMENT OF DEPRESSION

MMG004 GUIDELINES FOR THE USE OF HIGH DOSE VENLAFAXINE AND THE COMBINATION OF VENLAFAXINE AND MIRTAZAPINE IN THE TREATMENT OF DEPRESSION MMG004 GUIDELINES FOR THE USE OF HIGH DOSE VENLAFAXINE AND THE COMBINATION OF VENLAFAXINE AND MIRTAZAPINE IN THE TREATMENT OF DEPRESSION Page 1 of 13 Table of Contents Why we need this Guideline... 3 What

More information

The clinical response to the same dose

The clinical response to the same dose Making sense of CYP2D6 and CYP1A2 genotype vs phenotype O. Greg Deardorff, PharmD, BCPP, Victoria Jenne, PharmD, MPH, BCPS, and Lauren Leonard, PharmD The clinical response to the same dose of a drug may

More information

Variability Due to Genetic Differences

Variability Due to Genetic Differences 1 Variability Due to Genetic Differences Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland 2 Objectives Understand how between individual variation may contribute to :» drug

More information

Supplementary figures and tables. Figure A: Study schematic

Supplementary figures and tables. Figure A: Study schematic Supplementary figures and tables Figure A: Study schematic Figure B: Percent of patients with a normal (green), borderline (beige), abnormal (brown), or high (red) electrocardiogram 14-90 days after prescription

More information

Clinical Policy Title: Pharmacogenomic tests for psychiatric medications

Clinical Policy Title: Pharmacogenomic tests for psychiatric medications Clinical Policy Title: Pharmacogenomic tests for psychiatric medications Clinical Policy Number: 02.02.01 Effective Date: October 1, 2015 Initial Review Date: April 15, 2015 Most Recent Review Date: May

More information

Implémentation clinique de la pharmacogénétique

Implémentation clinique de la pharmacogénétique Implémentation clinique de la pharmacogénétique Vincent HAUFROID Cliniques Universitaires St Luc Université catholique de Louvain Louvain centre for Toxicology and Applied Pharmacology (LTAP) Pharmacogenetics:

More information

Genomind and The Genecept Assay

Genomind and The Genecept Assay Genomind and The Genecept Assay A Growing Problem of Psychiatric Conditions One in four adults, approximately 61.5 M American adults suffer from mental illness 1 ; depression will become the largest health

More information

Pharmacogenetics: Why some medications don t work - or make you feel worse - and what you can do about it.

Pharmacogenetics: Why some medications don t work - or make you feel worse - and what you can do about it. Pharmacogenetics: Why some medications don t work - or make you feel worse - and what you can do about it. Dan Doherty Senior Personalized Prescribing Consultant Genelex / YouScript April 2015 EDS NYC

More information